Insider Buying: Advaxis, Inc. (ADXS) Director Buys 3,000 Shares of Stock
Advaxis, Inc. (NASDAQ:ADXS) Director Roni Appel bought 3,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The shares were bought at an average cost of $3.80 per share, with a total value of $11,400.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of ADXS traded down $0.13 during mid-day trading on Thursday, hitting $3.69. The company’s stock had a trading volume of 37,877 shares, compared to its average volume of 1,224,870. Advaxis, Inc. has a one year low of $2.70 and a one year high of $30.60. The stock has a market capitalization of $21.05 million, a price-to-earnings ratio of -0.19 and a beta of 3.95.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported $0.18 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.43. Advaxis had a negative return on equity of 101.51% and a negative net margin of 140.12%. The company had revenue of $19.69 million during the quarter. Equities research analysts anticipate that Advaxis, Inc. will post -2.4 EPS for the current fiscal year.
A number of brokerages have issued reports on ADXS. HC Wainwright set a $4.00 target price on Advaxis and gave the stock a “hold” rating in a research report on Friday, April 5th. ValuEngine cut Advaxis from a “buy” rating to a “hold” rating in a research report on Friday, January 25th. Finally, Zacks Investment Research raised Advaxis from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research report on Wednesday, February 20th.
Advaxis Company Profile
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Featured Story: Trading Strategy Methods and Types
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.